Today’s show discussed biosimilar development from a clinical pharmacology perspective. I describe what biosimilar products are and the necessary comparisons to the reference product. I review requirements for PK similarity, PD similarity, immunogenicity, and safety. I also touch on the idea of interchangeability between the biosimilar and reference products.
Links discussed in the show:
- FDA Guidance on Clinical Pharmacology Data to support Biosimilarity (May 2016)
- FDA Guidance on Demonstrating Interchangeability (May 2019)
- FDA Q&A on Biosimilarity and Interchangeability (Sep 2023)
- You can connect with me on LinkedIn and send me a message
- Send me a message
- Sign up for my newsletter
Copyright Teuscher Solutions LLC
All Rights Reserved
